ArticleBiosensors2026
Rapid Detection of Fumonisin B1 Using a Fluorescent Aptasensor with Plasmon-Modified Graphene Oxide as a Quencher.
Article in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Fumonisin B1 (FB1) is a secondary metabolite produced by Fusarium species, exhibiting strong toxicity and classified as a Group 2B carcinogen by the International Agency for Research on Cancer. It poses a significant threat to both human and animal health. Therefore, developing a simple and reliable method for FB1 detection and analysis is imperative. In this study, a biosensor based on nucleic acid aptamers was developed, utilizing plasma-modified graphene oxide (mGO) as a fluorescence quencher for FB1 detection. This system leverages the interaction between mGO and FAM-APT (a nucleic acid aptamer labeled with 5-carboxyfluorescein, FAM), achieving fluorescence quenching through fluorescence resonance energy transfer (FRET) under excitation at 490 nm and emission at 520 nm. In the presence of FB1, FAM-APT specifically binds to FB1 and dissociates from the mGO surface, resulting in fluorescence recovery. Quantitative detection of FB1 was achieved by measuring the differential fluorescence intensity. The biosensor demonstrated excellent linearity over a concentration range of 10 to 5 × 10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.